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Favorable Modifiable Cardiovascular Risk Profile Is Associated With
Lower Healthcare Costs Among Cancer Patients: The 2012–2013
Medical Expenditure Panel Survey
Jai Singh, MD;* Javier Valero-Elizondo, MD, MPH;* Joseph A. Salami, MD, MPH; Haider J. Warraich, MD; Oluseye Ogunmoroti, MD, MPH;
Erica S. Spatz, MD, MHS; Nihar Desai, MD, MPH; Jamal S. Rana, MD, PhD; Salim S. Virani, MD, PhD; Ron Blankstein, MD; Michael J. Blaha,
MD, MPH; Khurram Nasir, MD, MPH
Background-—Atherosclerotic cardiovascular disease (ASCVD) and cancer are among the leading causes of economic burden,
morbidity, and mortality in the United States. We aimed to quantify the overall impact of cardiovascular modifiable risk factor (CRF)
profile on healthcare expenditures among those with and without ASCVD and/or cancer.
Methods and Results-—The 2012–2013 Medical Expenditure Panel Survey, a nationally representative adult sample
(≥40 years), was utilized for the study. Variables included ASCVD, CRF (hypertension, diabetes mellitus, hypercholesterolemia,
smoking, physical activity and/or obesity), and cancer (all). Two-part econometric models analyzed cost data. Medical
Expenditure Panel Survey participants (n=27 275, 599 years, 52% female) were studied and 14% had cancer, translating to
25.6 million US adults over 40 years of age. A higher prevalence of ASCVD was noted in those with versus without cancer
(25% versus 14%). Absence of ASCVD and a more favorable CRF profile were associated with significantly lower expenditures
across the spectrum of cancer diagnosis. Among cancer patients, the adjusted mean annual cost for those with and without
ASCVD were $10 852 (95% confidence interval [8917, 12 788]) and $6436 (95% confidence interval [5531, 7342]). Among
cancer patients without ASCVD, adjusted annual healthcare expenditures among those with optimal versus poor CRF profile
were $4782 and $7256.
Conclusions-—In a nationally representative US adult population, absence of ASCVD and a favorable CRF profile were associated
with significantly lower medical expenditure among cancer patients. This provides estimates to continue better cardiovascular
management and prevention practices, while contextualizing the burden of cancer. ( J Am Heart Assoc. 2018;7:e007874. DOI:
10.1161/JAHA.117.007874.)
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A therosclerotic cardiovascular disease (ASCVD) andcancer are among the leading causes of economic
burden, morbidity, and mortality in the United States.1 Nearly
half of all deaths in the United States can be attributed to
either cancer or ASCVD. The annual direct and indirect cost of
ASCVD and cancer in the United States is an estimated
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$844.4 billion dollars, which is projected to double by
2030.2–4 In addition to an aging population, a growing
number of cancer survivors are expected to increase from
15.5 to 20 million over the next decade, and in whom ASCVD
is one of the most common causes of non–cancer-related
deaths.5,6
An emerging paradigm, which continues to evolve, is the
inextricable link between ASCVD and cancer through common
modifiable risk factors such as tobacco use, obesity, diabetes
mellitus, diet quality, and physical activity. A scientific
statement from 2004 endorsed by the American Heart
Association, American Cancer Society, and American Dia-
betes Association called for more collaborative and effective
preventive healthcare strategies by targeting these shared
risk factors.7 Cancer survivorship begins at the time of
diagnosis, and many face increased healthcare expenditures
compared with individuals without a history of cancer, which
can lead to a reduced use of preventive services and
preventive medications.8–10 Although there are some reports
highlighting optimal cardiovascular risk factor (CRF) profile in
middle age being associated with reduced cardiovascular
costs later in life, the impact of ASCVD and global CRF on
healthcare costs and resource utilization among cancer
survivors is not well described.11,12
The goal of this study was to detail the healthcare costs
for cancer patients across the spectrum of ASCVD status
and varying modifiable CRF profiles in a nationally repre-
sentative population. We hypothesized that a favorable CRF
profile will be associated with significantly lower direct
healthcare expenditure and resource utilization in cancer
survivors.
Methods
Design
The Medical Expenditure Panel Survey (MEPS) data sets
and codebooks used for this study are available to the
public, and can be accessed on the Agency for Healthcare
Research and Quality website at: https://meps.ahrq.gov/me
psweb/.13 We conducted a retrospective study that utilized
data from the MEPS, 2012 and 2013. The MEPS, led by the
Agency for Healthcare Research and Quality, is a set of large-
scale, national survey about individuals and families, their
medical providers, and their employers. The Household
Component of the MEPS collects data about health services
used, their frequency and cost, charges, source of payment,
income, employment, as well as ample data on insurance
used by and available to US workers.13 The MEPS respon-
dents are enrolled for 2 years of data collection, with a new
panel beginning each year. The sampling frame for the MEPS-
Household Component is drawn from respondents to the
National Health Interview Survey and the design of the MEPS-
Household Component survey includes sampling weights,
stratification, and clustering. The MEPS sampling weights
incorporate adjustment for the complex sample design and
reflect survey nonresponse and population totals from the
Current Population Survey.13
In order to increase the study’s population, we merged
2012 and 2013 data, and used (from the MEPS Household
Component) the full-year consolidated data files and medical
conditions files. The full-year consolidated data files include
most demographics on a person-level, while the medical
conditions files include each diagnosis a person has, which
after being transcribed verbatim at each survey, are translated
into International Classification of Diseases, 9th Edition,
Clinical Modification (ICD-9-CM) by professional coders. MEPS
also allows categorization by Clinical Classification Software,
a tool from Healthcare Cost and Utilization Project that
groups ICD-9-CM codes into meaningful clinical categories.14
All files were linked together in order to determine accurate
results for each individual. Since MEPS information is
publically available, de-identified data-files, it was exempt
from institutional review board review.15
Participants
Initially, 75 402 individuals were surveyed between 2012 and
2013. We limited our study population to US adults ≥40 years
of age (because of the low prevalence of established ASCVD
among adults aged 18–39 years), who had a positive
sampling weight (to best estimate nationally representative
results), and a body mass index≥18.5 kg/m2 (given that they
often represent a sicker patient population), reaching a study
population of 25 275 noninstitutionalized individuals.
Clinical Perspective
What Is New?
• In this study, we noted a higher prevalence of atheroscle-
rotic cardiovascular disease as well as poor cardiovascular
disease risk profile among cancer survivors.
• Absence of atherosclerotic cardiovascular disease and
presence of optimal cardiovascular risk profile among
cancer survivors was associated with a significantly lower
overall medical expenditure and resource utilization, includ-
ing prescription medications, hospitalizations, emergency
department, and outpatient visits.
What Are the Clinical Implications?
• These results support population healthcare models empha-
sizing prevention of atherosclerotic cardiovascular disease
and improvement of cardiovascular risk factor profiles to
favorably impact the rising burden of healthcare expendi-
tures among cancer survivors.
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Study Variables
Individuals in the study population were classified into our
outcome variables based on presence of either a prior
diagnosis (ascertained by ICD-9-CM or Clinical Classification
Software codes, Table S1), or self-report for any of the
following: ASCVD (coronary artery disease, cerebrovascular
disease, or peripheral artery disease), any cancer, and CRFs
(hypertension, diabetes mellitus, hypercholesterolemia, lack
of physical exercise [defined as not participating in moderate-
vigorous physical activity, ≥30 minutes, ≥5 times per week],
smoking and/or obesity [body mass index ≥30 kg/m2, a
constructed variable using self-reported weight and height]).
For CRFs, based on the presence of the individual risk factors,
survey participants were profiled as “Poor” (≥4 CRFs),
“Average” (3–2 CRFs), or “Optimal” (0–1 CRFs).
Outcome variables: expenditures and resource
utilization
Total annual direct medical expenditures were calculated for
each person. Data for this variable included expenditures from
all payer groups and out-of-pocket spending, including
information from hospitalizations, prescribed medications,
outpatient visits (hospital outpatient visits and office-based
visits), emergency department (ED) visits, and other expen-
ditures (dental visits, vision aid, home health care, and other
medical supplies). In a similar fashion, resource utilization
analysis assessed the total number of outpatient and ED
visits, number of hospitalizations and number of prescription
medications purchases/refills each surveyed individual
incurred. All expenditures were adjusted to 2013 US dollars
by use of the gross domestic product .16
Covariates
Other variables included in the study were age (grouped in
40–54, 55–64, 65–74, and ≥75), sex, family income (grouped
in Poor/Near poor [<125% of the 2012 federal poverty level],
Low/Middle Income [125% to <400% federal poverty level],
and High Income [≥400% federal poverty level]), race/
ethnicity, employment, insurance type, education, geograph-
ical region, and modified Charlson Comorbidity Index (without
cardiovascular components).
Statistical Analysis
For comparison of demographic characteristics in our sample,
v2 tests were performed.17 Because of the right-skewedness
of expenditures data (i.e. most expenditures are seen in only a
small proportion of the population), 2-part models were
utilized to study expenditures.18 Two-part models are often
used to model healthcare expenditures, and are the product
of (1) the probability that any given individual had any
expenditures; and (2) their mean expenditures.19 The first part
of the model consists of a probabilistic regression model
(probit), which estimates the probability of zero versus
positive expenditures. Contingent upon having a positive
annual healthcare expenditure, a generalized linear model
(glm) with gamma distribution and a logarithmic-link function
estimates the average expenditure per capita19,20; we deter-
mined the distribution of the glm using the modified Park
Test.21 For resource utilization, unadjusted and adjusted
logistic regression models were utilized. Unadjusted means
and proportions were calculated, adjusting for the survey
design and sampling weight. For all statistical analyses,
P<0.05 was considered statistically significant. All analyses
were carried out using Stata, version 13.1 (StataCorp, LP,
College Station, TX). Total and Marginal expenditures were
estimated using the “margins” command after the 2-part
models.19 All analyses took into consideration the MEPS
complex survey design.
Results
Population Characteristics
The final study population consisted of 27 275 participants
≥40 years of age (599 years, 52% female), which translates
to 141.6 million US adults; demographic information is
presented in Table 1. Overall, 14% had cancer, translating to
25.6 million of the noninstitutionalized adult population in the
United States. Those with cancer were more likely to be older,
female, have ASCVD, have poor CRF profile, and a higher
burden of comorbid conditions. In the total study population
with cancer, 1434 (26.7%) had optimal, 2361 (50.6%) had
average, and 1126 (22.7%) had poor CRF profile, translating to
6.8, 12.9, and 5.8 million individuals in the United States,
respectively.
Healthcare Expenditures
Average per-capita healthcare expenditures estimated using
univariate and multivariate models by CRF profile, cancer, and
ASCVD status are shown in Table 2. Presence of cancer was
associated with increased overall healthcare expenditures
compared with those without cancer across the spectrum of
ASCVD status and CRF profile. Cancer participants without
ASCVD and a poor CRF profile had a mean annual expenditure
of $11 191 compared with $8116 among those with an
optimal CRF profile (Table 2, model 1). Additional adjustments
for covariates including demographics, socioeconomic fac-
tors, insurance, and comorbid conditions continued to show a
robust association with $7256 (95% confidence interval [CI],
5245–9266) versus $4782 (95% CI, 3764–5800) mean annual
expenditure of cancer participants without ASCVD and with
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Table 1. Baseline Characteristics From Adults ≥40 Years of Age, With and Without Cancer, From the MEPS Survey 2012–2013
All Cancer No Cancer P Value
Sample (N) 27 275 3951 23 324
Weighted sample 141 619 336 25 610 059 116 009 277
Age strata, n (weighted %) (y) <0.001
40–54 14 418 (42.4) 963 (18.2) 13 455 (47.7)
55–64 8152 (27.2) 1076 (24.8) 7076 (27.7)
65–74 4937 (17.6) 1203 (28.5) 3734 (15.2)
≥75 3366 (12.8) 1157 (28.4) 2209 (9.4)
Sex, n (weighted %) <0.001
Female 39 365 (52.2) 2913 (54.9) 36 452 (51.6)
Male 36 037 (47.8) 2008 (45.1) 34 029 (48.4)
Race/ethnicity, n (weighted %) <0.001
Non-Hispanic white 27 747 (70.9) 3390 (87.3) 24 357 (67.2)
Non-Hispanic black 15 646 (10.9) 690 (5.5) 14 956 (12.1)
Non-Hispanic Asian 5410 (4.9) 151 (1.5) 5259 (5.6)
Non-Hispanic other/multiple 2219 (1.9) 74 (1.1) 2145 (2.1)
Hispanic 24 380 (11.5) 616 (4.6) 23 764 (13.0)
Atherosclerotic cardiovascular disease, n (weighted %) <0.001
Non-ASCVD 70 395 (84.3) 3738 (74.9) 66 657 (86.4)
ASCVD 5007 (15.7) 1183 (25.1) 3824 (13.6)
CRF profile, n (weighted %) <0.001
Optimal 48 893 (36.0) 1434 (26.7) 47 459 (38.0)
Average 20 121 (45.8) 2361 (50.6) 17 760 (44.7)
Poor 6388 (18.2) 1126 (22.7) 5262 (17.2)
Education, n (weighted %) <0.001
<High School 33 722 (13.9) 890 (11.9) 32 832 (14.3)
GED or high school diploma 29 967 (56.0) 2683 (55.4) 27 284 (56.2)
>College 11 550 (30.1) 1343 (32.8) 10 207 (29.5)
Insurance status, n (weighted %) <0.001
Private 37 641 (67.1) 2963 (66.7) 34 678 (67.2)
Public only 24 128 (21.5) 1639 (29.1) 22 489 (19.8)
Uninsured 13 633 (11.4) 319 (4.2) 13 314 (12.9)
Region, n (weighted %) <0.001
Northeast 12 254 (18.3) 796 (17.2) 11 458 (18.6)
Midwest 13 810 (21.8) 1066 (23.3) 12 744 (21.5)
South 28 178 (37.3) 1861 (36.9) 26 317 (37.4)
West 21 160 (22.5) 1198 (22.6) 19 962 (22.5)
Family income, n (weighted %) <0.001
Poor 18 124 (10.3) 757 (8.3) 17 367 (10.7)
Near poor 5033 (4.3) 285 (4.9) 4748 (4.2)
Low income 13 111 (12.8) 722 (13.8) 12 389 (12.6)
Middle income 20 719 (28.7) 1386 (26.5) 19 333 (29.1)
High income 18 415 (44.0) 1771 (46.4) 16 644 (43.4)
Continued
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poor CRF versus optimal CRF profiles, respectively (Table 2,
model 3). Highest adjusted marginal total healthcare expen-
diture of $10 852 (95% CI, 8917–12 788) was observed in
those with both cancer and ASCVD. In a sensitivity analysis,
we additionally added an interaction between presence of
cancer diagnosis and ASCVD/NON-ASCVD CRF Profiles, with
it being nonsignificant (P>0.1), thus proving that a cancer
diagnosis would not influence our results, and similar trends
should be expected. Figure details levels of specific expen-
ditures (hospitalizations, ED visits, prescription drugs, office-
based visits, and other) according to CRF profile, ASCVD, and
cancer status. Adjusting for covariates including demograph-
ics, insurance, socioeconomic status, as well as comorbid
conditions, individuals with cancer in the absence of ASCVD
and with a poor CRF profile spent an annual average of $2207
on hospitalizations and $1969 on prescription medications
compared with $1194 and $624 for cancer individuals with
optimal CRF profile, respectively.
Healthcare Resource Utilization
Table 3 summarizes healthcare utilization rates across cancer
and ASCVD status as well as CRF profile categories. Overall,
favorable CRF profile and the absence of ASCVD were
associated with significantly less use of healthcare resources
among individuals with cancer. Among cancer participants
without ASCVD, those with optimal versus poor CRF profile
were less likely to have an ED visit (10.3% versus 22.6%) or
any hospitalization (7.3% versus 15.1%). After adjusting for
key covariates, among individuals with cancer but without
ASCVD, those with optimal CRF profile had 72% lower odds of
being hospitalized (odds ratio, 0.28 [95% CI, 0.15–0.53]), 67%
lower odds of having an ED visit (odds ratio, 0.33 [95% CI,
0.27–0.41]), 61% lower odds of outpatient visit (odds ratio,
0.39 [95% CI, 0.17–0.89]), and 89% lower odds of purchas-
ing/refilling a prescription medication (odds ratio, 0.11 [95%
CI, 0.09–0.12]) compared with those with poor CRF profile.
Table 1. Continued
All Cancer No Cancer P Value
Modified Charlson Comorbidity Index*, n (weighted %) <0.001
0 67 098 (83.8) 2976 (62.1) 64 122 (88.6)
1 6737 (10.9) 576 (11.5) 6161 (10.8)
≥2 1567 (5.3) 1369 (26.4) 198 (0.6)
ASCVD indicates atherosclerotic cardiovascular disease; CRF, cardiovascular risk factor; GED, general equivalency diploma; MEP, Medical Expenditure Panel.
*Charlson Comorbidity Index without Cardiovascular components.
Table 2. Total Costs by Cancer, ASCVD, and CRF Profile
ASCVD
No ASCVD
CRF Profile
Poor Average Optimal
Expenditure (95% CI) Expenditure (95% CI) Expenditure (95% CI) Expenditure (95% CI)
Model 1
Cancer $15 906 (14 335, 17 477) $11 191 (9137, 13 244) $9129 (8087, 10 171) $8116 (5608, 10 623)
No cancer $11 556 (10 608, 12 503) $7842 (7039, 8644) $4413 (4123, 4703) $2697 (2477, 2918)
Model 2
Cancer $14 001 (11 773, 16 228) $9639 (7486, 11 793) $6712 (5849, 7574) $6309 (4380, 8238)
No cancer $9972 (8630, 11 313) $7034 (6132, 7936) $3698 (3447, 3948) $2446 (2237, 2655)
Model 3
Cancer $10 852 (8917, 12 788) $7256 (5245, 9266) $5306 (4715, 5896) $4782 (3764, 5800)
No cancer $9443 (8316, 10 569) $6790 (6009, 7572) $3954 (3691, 4218) $2841 (2542, 3140)
Model 1: unadjusted. Model 2: adjusted for age, sex, socioeconomic status, race/ethnicity, insurance type, and geographical region. Model 3: adjusted for “model 2” plus Modified
Charlson Comorbidity Index (without cardiovascular components). ASCVD indicates atherosclerotic cardiovascular disease; CI, confidence interval; CRF, cardiovascular risk factor.
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Discussion
Previous studies have evaluated the financial burden associated
with cancer survivorship4,8,10,22,23; however, to the authors’
knowledge, this is the first attempt to contextualize the
economic impact of ASCVDand CRF profiles on cancer survivors
in a contemporary national representative sample of the US
population.We found a higher prevalence of ASCVD (25% versus
14%) and lower likelihood of an optimal CRF profile (27% versus
38%) among cancer survivors compared with those without
cancer. Additionally, we found significantly reduced healthcare
utilization and expenditures among cancer survivors without
ASCVD, and especially among those with optimal CRF profile.
Our results are consistent with prior reports highlighting the
increased burden of ASCVD and CRF in cancer survivors.5,24–26
Several contributing factors to this observation include com-
mon risk factors, rapidly growing survivorship population with
the majority over the age of 65, and potentially cardiotoxic
effects from cancer therapies themselves.6,24,27 Many of the
major shared risk factors between cancer and ASCVD are
incorporated into the American Heart Association’s “Strategic
Impact Goals for 2020,” which introduced the Life’s Simple 7
(smoking status, physical activity, eating pattern, body weight,
blood cholesterol, blood glucose, and blood pressure) as a
population-level health-promotion strategy that has been
shown to improve overall cardiovascular outcomes.28,29 Addi-
tionally, adherence to more components in American Heart
Association’s Life’s Simple 7 appears to be associated with a
lower risk of incident cancer even when smoking was removed
from the score.30 In a large retrospective cohort, adherence to
cancer guidelines for obesity, physical activity, and diet were
associated with a reduction of cancer and ASCVD mortality.31
Optimal management of cancer survivors involves increased
awareness of worse oncological and cardiovascular outcomes
in individuals with ASCVD and CRF, and early recognition and
aggressive management of shared risk factors. As noted in our
study (Figure), presence of ASCVD and poor risk profile in
absence of ASCVD was not only associated with much higher
subspecific absolute costs, but also a significant proportion of
costs (30%) were related to hospitalizations. On the other hand,
among cancer patients in absence of a diagnosis of ASCVD,
among patients with average and optimal CRF, hospitalizations
contributed to nearly 15% of overall expenditures, with a major
proportion (40%) of all costs related to outpatient visits.
These findings support the focus of current healthcare reforms
for value-based health care, emphasizing an integrated popu-
lation health on lowering overall healthcare costs by shifting
care from hospital-based services to ambulatory. Our results
provide cost estimates for potential cost savings by incorpo-
rating preventive strategies of modifiable CRF for cancer
survivors to mitigate progression to ASCVD and reduce the
associated comorbid cost burden.32
Study Limitations
Several limitations should be noted. First, we could not break
down cost by type or stage of cancer, or whether active
treatment for cancer was being delivered. Cancer survivors
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Figure. Mean per capita healthcare expenditures by ASCVD, cardiovascular risk factor profile, and cancer
status. ASCVD indicates atherosclerotic cardiovascular disease; ED, emergency department. Weighted and
adjusted for age, sex, socioeconomic status, race/ethnicity, insurance type, geographic region, modified
Charlson Comorbidity Index (without Cardiovascular components), and modifiable risk factors (only
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Table 3. Resource Utilization Stratified by ASCVD, Cancer, and CRF Profile
ASCVD
No ASCVD
CRF Profile
Poor Average Optimal
Hospitalizations
Proportion with any hospitalization
Cancer 0.2791 0.1509 0.1155 0.0731
No cancer 0.1991 0.1019 0.0593 0.025
Average hospitalizations
Cancer 1.43 1.36 1.28 1.27
No cancer 1.42 1.4 1.19 1.15
OR for any hospitalization
Cancer
Unadjusted Ref 0.46 (0.40, 0.53) 0.34 (0.29, 0.39) 0.20 (0.13, 0.32)
Adjusted* Ref 0.53 (0.40, 0.70) 0.43 (0.42, 0.44) 0.28 (0.15, 0.53)
No cancer
Unadjusted Ref 0.46 (0.38, 0.55) 0.25 (0.17, 0.38) 0.10 (0.08, 0.14)
Adjusted* Ref 0.53 (0.45, 0.64) 0.34 (0.23, 0.51) 0.16 (0.13, 0.20)
ED
Proportion with any ED visits
Cancer 0.3091 0.2257 0.1708 0.1027
No cancer 0.2634 0.1721 0.1215 0.0717
Average ED visits
Cancer 1.66 1.31 1.44 1.5
No cancer 1.58 1.52 1.36 1.27
OR for any ED visits
Cancer
Unadjusted Ref 0.65 (0.49, 0.87) 0.46 (0.20, 1.05) 0.26 (0.19, 0.34)
Adjusted Ref 0.72 (0.51, 1.01) 0.55 (0.25, 1.20) 0.33 (0.27, 0.41)
No cancer
Unadjusted Ref 0.58 (0.42, 0.81) 0.39 (0.20, 0.73) 0.22 (0.16, 0.29)
Adjusted* Ref 0.58 (0.45, 0.75) 0.44 (0.25, 0.77) 0.26 (0.20, 0.35)
Outpatient visits
Proportion with any outpatient visits
Cancer 0.9759 0.9588 0.9542 0.911
No cancer 0.9188 0.9026 0.7956 0.6837
Average outpatient visits
Cancer 18.02 13.4 13.56 11.04
No cancer 12.7 10.53 8.13 6.95
OR for any outpatient visits
Cancer
Unadjusted Ref 0.58 (0.16, 2.12) 0.52 (0.25, 1.08) 0.25 (0.14, 0.47)
Adjusted* Ref 0.68 (0.11, 4.16) 0.70 (0.45, 1.09) 0.39 (0.17, 0.89)
Continued
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were defined as any individual who has ever been diagnosed
with cancer regardless of duration as previously described.6
Second, the MEPS data only capture a fraction of total
national health expenditures for cancer patients. For example,
nursing home expenditures attributable to cancer are
excluded.33 Cancer patients with advanced disease were
likely not able to participate in the survey, further underes-
timating cancer costs. The true burden of cancer goes beyond
medical costs and includes lost productivity, stress, mental
health, costs for travel and child care, and costs incurred by
caretakers.34 Other analyses have reported an underestima-
tion of total medical expenditures from MEPS data, which all
suggest our results are a conservative estimate for the burden
of modifiable CRF on cancer patients as well as the estimated
savings from prevention strategies,33,35,36 therefore strength-
ening our findings. Third, because cancer, ASCVD, and
modifiable CRF were self-reported, there is likely an under-
representation of the true national prevalence, as has
previously been described.37,38 The prevalence of ASCVD in
this study was lower than previous national estimates (15.7%
versus 36%), in part because we excluded hypertension, as it
was included in the CRF profile.2 Fourth, lack of information
on dietary habits did not allow us to include this important
modifiable risk factor. Additionally, because of the lack of
clinical factors (blood pressure, fasting blood glucose, and
total cholesterol), we were not able to calculate American
Heart Association’s ideal health cardiovascular status (Life’s
Simple 7). Fifth, there is a risk of residual confounding from
unmeasured characteristics that could affect our study
outcomes, despite our best attempts to comprehensively
control for the most importantly observed contributing
variables. Lastly, the results only apply to the noninstitution-
alized adult US population.
Conclusions
From a contemporary nationally representative population, we
found that the absence of ASCVD and a favorable cardiovas-
cular risk factor profile among cancer survivors was associ-
ated with significantly lower healthcare expenditure and
resource utilization. These results provide robust estimates
for potential healthcare savings as preemptive strategies
continue to become integrated into new healthcare delivery
models, for increased awareness and prevention of ASCVD,
Table 3. Continued
ASCVD
No ASCVD
CRF Profile
Poor Average Optimal
No cancer
Unadjusted Ref 0.82 (0.79, 0.85) 0.34 (0.28, 0.42) 0.19 (0.17, 0.22)
Adjusted* Ref 0.98 (0.76, 1.25) 0.45 (0.31, 0.66) 0.27 (0.22, 0.32)
Prescription medications
Proportion with any purchase/refills
Cancer 0.9792 0.9732 0.9473 0.7788
No cancer 0.9391 0.937 0.7734 0.5385
Average purchase/refills
Cancer 42.22 40.18 23.85 13.55
No cancer 39.27 35.21 18.42 9.72
OR for any purchase/refills
Cancer
Unadjusted Ref 0.77 (0.48, 1.24) 0.38 (0.18, 0.80) 0.07 (0.06, 0.09)
Adjusted* Ref 0.92 (0.55, 1.54) 0.51 (0.25, 1.07) 0.11 (0.09, 0.12)
No cancer
Unadjusted Ref 0.97 (0.45, 2.06) 0.22 (0.17, 0.29) 0.08 (0.05, 0.11)
Adjusted* Ref 1.27 (0.71, 2.27) 0.32 (0.26, 0.38) 0.12 (0.08, 0.18)
Odds ratios are presented as: OR (95% CI). ASCVD indicates atherosclerotic cardiovascular disease; CI, confidence interval; CRF, cardiovascular risk factor; ED, emergency department; OR,
odds ratio.
*Adjusted for age, sex, socioeconomic status, race/ethnicity, insurance type, geographical region, and Modified Charlson Comorbidity Index (without cardiovascular components).
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and improvement in cardiovascular risk factor profiles among
those with and without diagnosed cancer.
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Table S1. ICD-9-CM codes, MEPS 2012-2013. 
 
Diagnosis ICD-9-CM 
ASCVD  
        Acute Myocardial Infarction 410 
        Angina Pectoris 413 
        Other Chronic Ischemic Heart Disease 414 
Cerebrovascular Disease  
        Precerebral Artery Occlusion 433 
        Cerebral Artery Occlusion 434 
        Transient Cerebral Ischemia 435 
        Acute, But Ill-Defined, Cerebrovascular Disease 436 
        Other And Ill-Defined Cerebrovascular Disease 437 
CRF  
        Hypertension 401 
        Diabetes Mellitus 250 
        Disorders Of Lipoid Metabolism 272 
  
Diagnosis CCS 
        Cancer 11 - 44 
 
ICD-9-CM, International Classification of Diseases, 9th Edition, Clinical Modification; ASCVD, 
atherosclerotic cardiovascular disease; CRF, cardiovascular risk factor; CCS, clinical 
classification software diagnoses. 
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